Biogen Inc. (Nasdaq: BIIB) announced today that Michael McDonnell, Executive Vice President and Chief Financial Officer, will retire from his role on February 28, 2025. Upon his retirement, Robin Kramer, currently Biogen’s Chief Accounting Officer, will step into the Chief Financial Officer (CFO) role. Over the coming months, Mr. McDonnell will work closely with Ms. Kramer to facilitate a smooth leadership transition.
Since joining Biogen in August 2020, Mr. McDonnell has played a critical role in driving the company’s goal of sustainable growth. His efforts included realigning Biogen’s cost structure and strategically allocating capital towards growth initiatives. He also led recent acquisitions of late-stage assets and fostered a culture of financial discipline within the company.
“On behalf of the Board and our leadership team, I thank Mike for his dedicated service to Biogen. His leadership through our Fit for Growth program has been invaluable,” said Christopher A. Viehbacher, Biogen’s President and CEO. “I am also pleased to announce Robin Kramer as our next CFO. Her deep business understanding and leadership experience make her exceptionally qualified to lead our finance team.”
Ms. Kramer joined Biogen in 2018 and has served as Senior Vice President and Chief Accounting Officer since 2020, overseeing key finance functions, including Treasury, global procurement, and Global Business Services. She has also been instrumental in supporting Biogen’s M&A strategy and growth initiatives. Prior to Biogen, Ms. Kramer held senior finance roles at Hertz Global Holdings, Fisher Scientific, and Gillette, and was an audit partner at Deloitte, Ernst & Young, and Arthur Andersen. She also serves on the boards of Armata Pharmaceuticals and the Center for Women and Enterprise.
“I am honored to take on the role of CFO and contribute to Biogen’s strategic transformation for patients, partners, and shareholders,” said Ms. Kramer. “Mike has been an incredible mentor, and I look forward to working with Chris, the Executive Committee, and the Board to continue delivering on Biogen’s financial objectives.”
Reflecting on his tenure, Mr. McDonnell expressed gratitude for his time at Biogen, adding, “It has been a privilege to serve as Biogen’s CFO. I am confident Robin will excel in this role, and I look forward to seeing Biogen’s continued success.
